156 related articles for article (PubMed ID: 31013984)
1. Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data.
Schneider D; Oskamp A; Holschbach M; Neumaier B; Bauer A; Bier D
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 31013984
[TBL] [Abstract][Full Text] [Related]
2. Influence of incubation conditions on microsomal metabolism of xanthine-derived A
Schneider D; Bier D; Bauer A; Neumaier B; Holschbach M
J Pharmacol Toxicol Methods; 2019; 95():16-26. PubMed ID: 30476620
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
5. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments.
Elmenhorst D; Kroll T; Wedekind F; Weisshaupt A; Beer S; Bauer A
J Nucl Med; 2013 Aug; 54(8):1411-9. PubMed ID: 23740103
[TBL] [Abstract][Full Text] [Related]
6. Species Differences in Microsomal Metabolism of Xanthine-Derived A
Schneider D; Bier D; Holschbach M; Bauer A; Neumaier B
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803861
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET.
Bauer A; Holschbach MH; Cremer M; Weber S; Boy C; Shah NJ; Olsson RA; Halling H; Coenen HH; Zilles K
J Nucl Med; 2003 Oct; 44(10):1682-9. PubMed ID: 14530487
[TBL] [Abstract][Full Text] [Related]
8. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion.
Bauer A; Langen KJ; Bidmon H; Holschbach MH; Weber S; Olsson RA; Coenen HH; Zilles K
J Nucl Med; 2005 Mar; 46(3):450-4. PubMed ID: 15750158
[TBL] [Abstract][Full Text] [Related]
9. Applications of high throughput microsomal stability assay in drug discovery.
Di L; Kerns EH; Ma XJ; Huang Y; Carter GT
Comb Chem High Throughput Screen; 2008 Jul; 11(6):469-76. PubMed ID: 18673274
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies.
Matusch A; Meyer PT; Bier D; Holschbach MH; Woitalla D; Elmenhorst D; Winz OH; Zilles K; Bauer A
Nucl Med Biol; 2006 Oct; 33(7):891-8. PubMed ID: 17045169
[TBL] [Abstract][Full Text] [Related]
11. Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors.
Barret O; Hannestad J; Vala C; Alagille D; Tavares A; Laruelle M; Jennings D; Marek K; Russell D; Seibyl J; Tamagnan G
J Nucl Med; 2015 Apr; 56(4):586-91. PubMed ID: 25698783
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction.
Bowman CM; Benet LZ
J Pharm Sci; 2019 Jul; 108(7):2500-2504. PubMed ID: 30817922
[TBL] [Abstract][Full Text] [Related]
13. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
Ashforth EI; Carlile DJ; Chenery R; Houston JB
J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
[TBL] [Abstract][Full Text] [Related]
14. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of 18F-MNI698: an 18F-labeled radiotracer for imaging of serotonin 4 receptors in brain.
Tavares AA; Caillé F; Barret O; Papin C; Lee H; Morley TJ; Fowles K; Holden D; Seibyl JP; Alagille D; Tamagnan GD
J Nucl Med; 2014 May; 55(5):858-64. PubMed ID: 24686782
[TBL] [Abstract][Full Text] [Related]
16. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.
Carlile DJ; Zomorodi K; Houston JB
Drug Metab Dispos; 1997 Aug; 25(8):903-11. PubMed ID: 9280396
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.
Matsunaga N; Ufuk A; Morse BL; Bedwell DW; Bao J; Mohutsky MA; Hillgren KM; Hall SD; Houston JB; Galetin A
Drug Metab Dispos; 2019 Mar; 47(3):215-226. PubMed ID: 30593544
[TBL] [Abstract][Full Text] [Related]
18. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
Soars MG; Burchell B; Riley RJ
J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
[TBL] [Abstract][Full Text] [Related]
19. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.
Chau WF; Black AM; Clarke A; Durrant C; Gausemel I; Khan I; Mantzilas D; Oulie I; Rogstad A; Trigg W; Jones PA
Nucl Med Biol; 2015 Sep; 42(9):711-9. PubMed ID: 26072270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
